Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAG-17 in ALS with SOD1 Mutation
NCT06556394Phase 1Recruiting
- Sponsor
- Ractigen Therapeutics
- Start
- Dec 2024
- Primary completion
- Feb 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing RAG-17 with Placebo (2 arms). Primary endpoint: Adverse Events (AEs) at 57 days. Started Dec 2024; status: recruiting.
02
Drugs
RAG-17
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06556394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556394.